Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin

Lindsay J. Marshall, Wilson Oguejiofor, Robert Price, Jagdeep Shur*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The airways of most people with cystic fibrosis are colonized with biofilms of the Gram-negative, opportunistic pathogen Pseudomonas aeruginosa. Delivery of antibiotics directly to the lung in the form of dry powder aerosols offers the potential to achieve high local concentrations directly to the biofilms. Unfortunately, current aerosolised antibiotic regimes are unable to efficiently eradicate these biofilms from the airways. We investigated the ability of the innate antimicrobial, lactoferrin, to enhance the activity of two aminoglycoside antibiotics (tobramycin and gentamicin) against biofilms of P. aeruginosa strain PAO1. Biofilms were prepared in 96 well polystyrene plates. Combinations of the antibiotics and various lactoferrin preparations were spray dried. The bacterial cell viability of the various spray dried combinations was determined. Iron-free lactoferrin (apo lactoferrin) induced a 3-log reduction in the killing of planktonic cell by the aminoglycoside antibiotics (p < 0.01) and also reduced both the formation and persistence of P. aeruginosa biofilms (p < 0.01). Combinations of lactoferrin and an aminoglycoside displays potential as an effective new therapeutic strategy in the treatment of P. aeruginosa biofilms infections such as those typical of the CF lungs.

Original languageEnglish
Pages (from-to)399-406
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume514
Issue number2
Early online date11 Sep 2016
DOIs
Publication statusPublished - 5 Dec 2016

Bibliographical note

x

Keywords

  • antimicrobial protein
  • biofilms
  • cystic fibrosis
  • dry powder inhalers
  • pseudomonas aeruginosa
  • spray drying

Fingerprint Dive into the research topics of 'Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin'. Together they form a unique fingerprint.

  • Cite this